Molecular targeted drugs and immunity

Takashi Morisaki, Hideya Onishi, Hiroyuki Suzuki, Mitsuo Katano

Research output: Contribution to journalReview article

Abstract

Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.

Original languageEnglish
Pages (from-to)291-295
Number of pages5
JournalBiotherapy
Volume24
Issue number4
Publication statusPublished - Jul 1 2010

Fingerprint

Immunity
Pharmaceutical Preparations
Molecular Targeted Therapy
Neoplasms
Regulatory T-Lymphocytes
Natural Killer Cells
Molecular Biology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Morisaki, T., Onishi, H., Suzuki, H., & Katano, M. (2010). Molecular targeted drugs and immunity. Biotherapy, 24(4), 291-295.

Molecular targeted drugs and immunity. / Morisaki, Takashi; Onishi, Hideya; Suzuki, Hiroyuki; Katano, Mitsuo.

In: Biotherapy, Vol. 24, No. 4, 01.07.2010, p. 291-295.

Research output: Contribution to journalReview article

Morisaki, T, Onishi, H, Suzuki, H & Katano, M 2010, 'Molecular targeted drugs and immunity', Biotherapy, vol. 24, no. 4, pp. 291-295.
Morisaki T, Onishi H, Suzuki H, Katano M. Molecular targeted drugs and immunity. Biotherapy. 2010 Jul 1;24(4):291-295.
Morisaki, Takashi ; Onishi, Hideya ; Suzuki, Hiroyuki ; Katano, Mitsuo. / Molecular targeted drugs and immunity. In: Biotherapy. 2010 ; Vol. 24, No. 4. pp. 291-295.
@article{7a14347ca5224162a62b072fe13c8b7c,
title = "Molecular targeted drugs and immunity",
abstract = "Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.",
author = "Takashi Morisaki and Hideya Onishi and Hiroyuki Suzuki and Mitsuo Katano",
year = "2010",
month = "7",
day = "1",
language = "English",
volume = "24",
pages = "291--295",
journal = "Biotherapy",
issn = "0914-2223",
number = "4",

}

TY - JOUR

T1 - Molecular targeted drugs and immunity

AU - Morisaki, Takashi

AU - Onishi, Hideya

AU - Suzuki, Hiroyuki

AU - Katano, Mitsuo

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.

AB - Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.

UR - http://www.scopus.com/inward/record.url?scp=77955819977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955819977&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77955819977

VL - 24

SP - 291

EP - 295

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 4

ER -